Movement Alert｜Iovance Biotherapeutics, Inc. Rises 5.19% in Regular Trading, Q3 report date announcement revives attention

Market Focus10-27

On October 27, Iovance Biotherapeutics, Inc. rose 5.19% in Regular Trading, trading at $14.52 per share, with turnover of $39.06 million.

The direct catalyst was the company’s announcement that it will report third-quarter financial results and provide a corporate update on November 5, which brought the name back into focus.

Recent background has also remained supportive: late in September, Iovance Biotherapeutics, Inc. raised its full-year revenue guidance to $410 million-$420 million from $350 million-$370 million, above the $402.8 million market expectation, citing strong demand for Amtagvi and Proleukin. In addition, final Phase 2 data presented at ESMO showed lifileucel plus pembrolizumab delivered a 62.5% overall response rate and a 29.2% complete response rate in frontline advanced melanoma, helping sustain investor attention ahead of the November update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment